

Jiao Xie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5801288/publications.pdf>

Version: 2024-02-01

34
papers

600
citations

687220

13
h-index

642610

23
g-index

34
all docs

34
docs citations

34
times ranked

939
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 436-442.	1.1	96
2	Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation. <i>International Journal of Infectious Diseases</i> , 2014, 18, 62-67.	1.5	49
3	Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	42
4	Establishment of Paclitaxel-resistant Breast Cancer Cell Line and Nude Mice Models, and Underlying Multidrug Resistance Mechanisms in Vitro and in Vivo. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 6135-6140.	0.5	40
5	Linezolid versus vancomycin for the treatment of suspected methicillin-resistant <i>Staphylococcus aureus</i> nosocomial pneumonia: a systematic review employing meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 107-115.	0.8	39
6	Proteomic analysis of the proteins that are associated with the resistance to paclitaxel in human breast cancer cells. <i>Molecular BioSystems</i> , 2014, 10, 294-303.	2.9	28
7	Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 259-264.	1.1	25
8	Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 151-157.	1.1	25
9	Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections. <i>Pharmacotherapy</i> , 2015, 35, 797-804.	1.2	23
10	Pharmacokinetic/pharmacodynamic adequacy of echinocandins against <i>Candida</i> spp. in intensive care unit patients and general patient populations. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 397-402.	1.1	23
11	Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients. <i>International Journal of Infectious Diseases</i> , 2014, 22, 35-40.	1.5	22
12	Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2641-2649.	1.3	18
13	Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105943.	1.1	16
14	Quantitative analysis and pharmacokinetics study of tigecycline in human serum using a validated sensitive liquid chromatography with tandem mass spectrometry method. <i>Journal of Separation Science</i> , 2014, 37, 1396-1403.	1.3	15
15	Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit. <i>Pharmacotherapy</i> , 2016, 36, 757-765.	1.2	15
16	Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015, 53, 356-362.	0.3	15
17	Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis. <i>Annals of Pharmacotherapy</i> , 2018, 52, 965-973.	0.9	14
18	Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis. <i>Clinical Pharmacokinetics</i> , 2020, 59, 327-334.	1.6	13

#	ARTICLE	IF	CITATIONS
19	Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis. <i>Fundamental and Clinical Pharmacology</i> , 2016, 30, 459-465.	1.0	12
20	Population pharmacokinetics of polymyxin B: a systematic review. <i>Annals of Translational Medicine</i> , 2022, 10, 231-231.	0.7	12
21	Safety and Efficacy of Tigecycline in Intensive Care Unit Patients Based on Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 835-840.	1.0	11
22	Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 843-854.	0.8	9
23	The Adenosine Deaminase Gene Polymorphism Is Associated with Chronic Heart Failure Risk in Chinese. <i>International Journal of Molecular Sciences</i> , 2014, 15, 15259-15271.	1.8	8
24	Choosing Optimal Antifungal Agents To Prevent Fungal Infections in Nonneutropenic Critically Ill Patients: Trial Sequential Analysis, Network Meta-analysis, and Pharmacoeconomic Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	6
25	Fluconazole versus mould-active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost-effectiveness analysis. <i>International Journal of Hematology</i> , 2018, 107, 235-243.	0.7	5
26	A sensitive liquid chromatography-tandem mass spectrometry method for monitoring the caspofungin trough plasma concentration and its association with caspofungin efficacy in intensive-care-unit patients. <i>RSC Advances</i> , 2015, 5, 104806-104814.	1.7	4
27	Modeling and forecasting <i>Acinetobacter baumannii</i> resistance to set appropriate use of cefoperazone-sulbactam: Results from trend analysis of antimicrobial consumption and development of resistance in a tertiary care hospital. <i>American Journal of Infection Control</i> , 2015, 43, 861-864.	1.1	4
28	Determination of tigecycline in human lung epithelial cells and polymorphonuclear neutrophils by liquid chromatography/tandem mass spectrometry and its application in a cellular pharmacokinetics study. <i>Rapid Communications in Mass Spectrometry</i> , 2021, 35, e9112.	0.7	4
29	Population pharmacokinetics of ticarcillin in critically ill patients receiving extended daily diafiltration. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 351-355.	1.1	2
30	Determination of the Solubility, Dissolution Enthalpy, and Entropy of Icaritin in Acetone, Acetoacetate, Chloroform, and Light Petroleum. <i>Natural Product Communications</i> , 2020, 15, 1934578X2097149.	0.2	2
31	Potentially Hazardous Drug-Drug Interactions Associated With Oral Antineoplastic Agents Prescribed in Chinese Tertiary Care Teaching Hospital Settings: A Multicenter Cross-Sectional Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 808848.	1.6	1
32	Treatment efficacy of tigecycline in comparison to cefoperazone/ sulbactam alone or in combination therapy for carbapenem-resistant <i>Acinetobacter baumannii</i> infections. <i>Pakistan Journal of Pharmaceutical Sciences</i> , 2020, 33, 161-168.	0.2	1
33	Pharmacokinetic/Pharmacodynamic Target Attainment of Different Antifungal Agents in De-escalation Treatment in Critically Ill Patients: a Step toward Dose Optimization Using Monte Carlo Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	1.4	1
34	Determination and Characterization of the Uptake of Voriconazole in Human Lung Epithelial Cells by High-Performance Liquid Chromatography-Tandem Mass Spectrometry. <i>Analytical Letters</i> , 2017, 50, 304-314.	1.0	0